August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
13 citations
,
October 2017 in “Bioorganic & Medicinal Chemistry” Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
30 citations
,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
4 citations
,
March 2008 in “Journal of the American Academy of Dermatology” November 2011 in “ChemInform” October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
3 citations
,
May 2014 in “Urologia Journal” 5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
Cadd4 effectively reduces cholesterol levels without side effects.
6 citations
,
October 1993 in “Endocrinology” Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
87 citations
,
September 2006 in “Clinical Cancer Research” Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
February 1996 in “Clinical Pharmacology & Therapeutics” MK-386 reduces sebum DHT levels.
50 citations
,
March 2017 in “PeerJ” Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
1 citations
,
January 2004 in “Medicina de Familia SEMERGEN” Finasteride may help prevent prostate cancer.
September 2024 in “Uro-Technology Journal” February 2026 in “Case Reports in Dermatology” Finasteride can cause melasma, especially in people with darker skin.
September 2021 in “World journal of urology” The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
20 citations
,
June 1995 in “Tetrahedron Letters” New chemicals were made that can block an enzyme linked to hair loss, prostate growth, and acne.